Polyrizon Ltd. Retains Nasdaq Listing After Addressing Compliance Concerns, Aims to Regain Minimum Bid Price by October 2025

Reuters
Jul 15
<a href="https://laohu8.com/S/PLRZ">Polyrizon Ltd.</a> Retains Nasdaq Listing After Addressing Compliance Concerns, Aims to Regain Minimum Bid Price by October 2025

Raanana, Israel, July 15, 2025 - Polyrizon Ltd. (Nasdaq: PLRZ), a biotech company specializing in intranasal hydrogels, has successfully retained its listing on the Nasdaq Capital Market. Following a hearing on June 26, 2025, the Nasdaq Hearings Panel granted Polyrizon's request to continue its listing, provided the company complies with the Minimum Bid Price Rule by October 17, 2025. The company has committed to avoiding complex or dilutive financing instruments in future capital-raising activities and is implementing an internal control framework to ensure compliance with Nasdaq standards. CEO Tomer Izraeli expressed optimism about enhancing shareholder value and strengthening the company's business position.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9494649-en) on July 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10